A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer

A phase II study of the oral matrix metalloproteinase inhibitor, marimastat, in patients with inoperable gastric cancer

Gastroenterology ◽

10.1016/s0016-5085(98)82825-4 ◽

1998 ◽

Vol 114 ◽

pp. A688

Author(s):

G Tierney ◽

S.L. Parsons ◽

N.R. Griffin ◽

S.A. Watson ◽

R.J.C. Steele

Keyword(s):

Gastric Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metalloproteinase Inhibitor

Metastasis is strongly reduced by the matrix metalloproteinase inhibitor Galardin in the MMTV-PymT transgenic breast cancer model

Molecular Cancer Therapeutics ◽

10.1158/1535-7163.mct-08-0251 ◽

2008 ◽

Vol 7 (9) ◽

pp. 2758-2767 ◽

Cited By ~ 27

Author(s):

K. Almholt ◽

A. Juncker-Jensen ◽

O. D. Laerum ◽

K. Dano ◽

M. Johnsen ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Model ◽

Breast Cancer Model ◽

Molecular Interactions between Matrilysin and the Matrix Metalloproteinase Inhibitor Doxycycline Investigated by Deuterium Exchange Mass Spectrometry

Molecular Pharmacology ◽

10.1124/mol.104.006346 ◽

2005 ◽

Vol 67 (4) ◽

pp. 1128-1136 ◽

Cited By ~ 52

Author(s):

Ricardo A. García ◽

Dennis P. Pantazatos ◽

Christopher R. Gessner ◽

Katrina V. Go ◽

Virgil L. Woods ◽

...

Keyword(s):

Mass Spectrometry ◽

Molecular Interactions ◽

Deuterium Exchange ◽

Deuterium Exchange Mass Spectrometry

Exchange Mass Spectrometry ◽

The Matrix ◽

Modulation of airway remodeling-associated mediators by the antifibrotic compound, pirfenidone, and the matrix metalloproteinase inhibitor, batimastat, during acute lung injury in mice

European Journal of Pharmacology ◽

10.1016/s0014-2999(01)01209-2 ◽

2001 ◽

Vol 426 (1-2) ◽

pp. 113-121 ◽

Cited By ~ 53

Author(s):

Marianne Corbel ◽

Jérôme Lanchou ◽

Noëlla Germain ◽

Yannick Malledant ◽

Elisabeth Boichot ◽

...

Keyword(s):

Acute Lung Injury ◽

Lung Injury ◽

Airway Remodeling ◽

A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas

Investigational New Drugs ◽

10.1007/s10637-006-9031-6 ◽

2007 ◽

Vol 25 (4) ◽

pp. 359-367 ◽

Cited By ~ 26

Author(s):

Quincy S. C. Chu ◽

Bahram Forouzesh ◽

Samira Syed ◽

Monica Mita ◽

Garry Schwartz ◽

...

Keyword(s):

Soft Tissue ◽

Phase Ii ◽

Pharmacological Study ◽

Soft Tissue Sarcomas ◽

Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model

British Journal of Cancer ◽

10.1038/bjc.1996.549 ◽

1996 ◽

Vol 74 (9) ◽

pp. 1354-1358 ◽

Cited By ~ 35

Author(s):

SA Watson ◽

TM Morris ◽

SL Parsons ◽

RJ Steele ◽

PD Brown

Keyword(s):

Colorectal Cancer ◽

Therapeutic Effect ◽

Human Colorectal Cancer ◽

The matrix metalloproteinase inhibitor BB-1101 prevents experimental autoimmune uveoretinitis (EAU)

Clinical & Experimental Immunology ◽

10.1046/j.1365-2249.1999.01066.x ◽

1999 ◽

Vol 118 (3) ◽

pp. 364-370 ◽

Cited By ~ 13

Author(s):

Wallace ◽

Whiston ◽

Stanford ◽

Wells ◽

Gearing ◽

...

Keyword(s):

Experimental Autoimmune Uveoretinitis ◽

The Matrix ◽

Experimental Autoimmune

Influence of the matrix metalloproteinase inhibitor batimastat (BB-94) on periodontal bone destruction in Sprague-Dawley rats

Journal of Periodontal Research ◽

10.1111/j.1600-0765.2004.00740.x ◽

2004 ◽

Vol 39 (4) ◽

pp. 269-274 ◽

Cited By ~ 9

Author(s):

Magnus Jon Bjornsson ◽

Anne Havemose-Poulsen ◽

Kaj Stoltze ◽

Palle Holmstrup

Keyword(s):

Bone Destruction ◽

Sprague Dawley ◽

Sprague Dawley Rats ◽

Effects of the Matrix Metalloproteinase Inhibitor GM6001 on the Destruction and Alteration of Epithelial Basement Membrane During the Healing of Post-alkali Burn in Rabbit Cornea

Japanese Journal of Ophthalmology ◽

10.1007/s10384-005-0287-8 ◽

2006 ◽

Vol 50 (2) ◽

pp. 90-95 ◽

Cited By ~ 12

Author(s):

Tadashi Kato ◽

Shizuya Saika ◽

Yoshitaka Ohnishi

Keyword(s):

Basement Membrane ◽

Rabbit Cornea ◽

Alkali Burn ◽

Epithelial Basement Membrane ◽

The Matrix ◽

Epithelial Basement

Angiogenesis inhibition in metastatic hormone refractory prostate cancer (HRPC): A randomized phase II trial of two doses of the matrix metalloproteinase inhibitor (MMPI) BMS-275291

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.4647 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 4647-4647 ◽

Cited By ~ 4

Author(s):

P. N. Lara ◽

J. Longmate ◽

W. Stadler ◽

D. I. Quinn ◽

P. Twardowski ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Hormone Refractory Prostate Cancer ◽

Randomized Phase Ii ◽

The Matrix ◽

Hormone Refractory